CVS buying Target pharmacies in $1.9B deal; Merck KGaA to sell Sigma-Aldrich plant in Germany;

> CVS ($CVS) has agreed to buy Target's ($TGT) pharmacy and clinic business for $1.9 billion. Report

> The United Arab Emirates-based drug distributor Al Ittihad Drug Store (IDS) intends to build a manufacturing facility in Dubai as part of its plan to begin producing some of its own products. Report

> CPhI is now taking entries for an expanded list of awards. Release

> New England Biolabs is adding a 30,000-square-foot clean room to its facility in Ipswich, MA. Release

> Merck KGaA has agreed to sell a Sigma-Aldrich ($SIAL) solvents and inorganics manufacturing site in Seelze, Germany, as a condition of receiving the OK from the European Commission for Merck to complete its $17 million acquisition of the chemical and lab services company. Report (PDF)

> South African regulators say they will continue to inspect all local and some international active pharmaceutical ingredients facilities, although it has taken steps to expedite the process for API approval. Report

And Finally... Federal authorities have seized a 2011 BMW M3 and a 2010 luxury boat owned by Barry J. Cadden, the former shareholder and head pharmacist of New England Compounding Center (NECC), who has been indicted for his alleged part in a fatal fungal meningitis outbreak tied to drugs manufactured by NECC. Release

Suggested Articles

Gilead expects to sell 1 million to 1.5 million treatment courses of remdesivir in 2020. That means about $3.5 billion in sales, one analsyt figures.

Pfizer and BioNTech followed supply pacts in the U.S. and U.K. with a new deal to deliver 120 million vaccines to Japan in the first half of 2021.

Warp Speed's largest outlay to date, the funding will cover development and manufacturing scale-up of a vaccine that uses proven Sanofi technology.